Published in Proc Natl Acad Sci U S A on August 28, 2006
The immunoregulatory role of dopamine: an update. Brain Behav Immun (2009) 1.42
Serotonin provides an accessory signal to enhance T-cell activation by signaling through the 5-HT7 receptor. Blood (2006) 1.29
Characterization and function of the human macrophage dopaminergic system: implications for CNS disease and drug abuse. J Neuroinflammation (2012) 0.90
Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget (2016) 0.86
Vaccination strategies for Parkinson disease: induction of a swift attack or raising tolerance? Hum Vaccin Immunother (2014) 0.82
TFH-derived dopamine accelerates productive synapses in germinal centres. Nature (2017) 0.81
Dopamine receptors modulate cytotoxicity of natural killer cells via cAMP-PKA-CREB signaling pathway. PLoS One (2013) 0.81
Immunomodulatory Effects Mediated by Dopamine. J Immunol Res (2016) 0.75
Potential Roles of Peripheral Dopamine in Tumor Immunity. J Cancer (2017) 0.75
Enhancing the anti-lymphoma potential of 3,4-methylenedioxymethamphetamine ('ecstasy') through iterative chemical redesign: mechanisms and pathways to cell death. Invest New Drugs (2011) 0.75
Dopamine, T cells and multiple sclerosis (MS). J Neural Transm (Vienna) (2017) 0.75
Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev (2004) 5.89
Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci U S A (2005) 3.30
Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J Biol Chem (2004) 3.14
Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol (1993) 3.09
Germinal center cells express bcl-2 protein after activation by signals which prevent their entry into apoptosis. Eur J Immunol (1991) 2.71
B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation. Ann Neurol (2006) 2.52
Dual regulation of caspase activity by hydrogen peroxide: implications for apoptosis. FEBS Lett (1997) 2.02
Lymphocytes transport serotonin and dopamine: agony or ecstasy? Trends Immunol (2003) 1.79
The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity. J Biol Chem (2000) 1.60
A novel form of immune signaling revealed by transmission of the inflammatory mediator serotonin between dendritic cells and T cells. Blood (2005) 1.57
The dopamine inhibitor GBR 12909: selectivity and molecular mechanism of action. Eur J Pharmacol (1989) 1.35
Discovery of endogenous catecholamines in lymphocytes and evidence for catecholamine regulation of lymphocyte function via an autocrine loop. Proc Natl Acad Sci U S A (1994) 1.33
The 2000 Burkitt lymphoma trial in Malawi. Pediatr Blood Cancer (2005) 1.31
Inhibition of melanogenesis as an adjuvant strategy in the treatment of melanotic melanomas: selective review and hypothesis. Anticancer Res (1999) 1.29
Non-Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc (2005) 1.19
Complexity of the bi-directional neuroimmune junction in the spleen. Trends Pharmacol Sci (2004) 1.14
AIDS-related lymphoproliferative disease. Blood (2005) 1.13
Thioredoxin peroxidase-1 (peroxiredoxin-1) is increased in thioredoxin-1 transfected cells and results in enhanced protection against apoptosis caused by hydrogen peroxide but not by other agents including dexamethasone, etoposide, and doxorubicin. Arch Biochem Biophys (2001) 1.09
The serotonin transporter (SLC6A4) is present in B-cell clones of diverse malignant origin: probing a potential anti-tumor target for psychotropics. FASEB J (2005) 1.07
Measurements of catecholamine-mediated apoptosis of immunocompetent cells by capillary electrophoresis. Electrophoresis (1997) 1.04
Prevention of programmed cell death in Burkitt lymphoma cell lines by bcl-2-dependent and -independent mechanisms. Int J Cancer (1992) 1.03
Close encounters of the monoamine kind: immune cells betray their nervous disposition. Immunology (2005) 1.01
Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells. Blood (2002) 1.00
Thioredoxin prolongs survival of B-type chronic lymphocytic leukemia cells. Blood (2000) 1.00
Bcl-2 does not protect Burkitt's lymphoma cells from oxidant-induced cell death. Blood (1997) 0.99
The extrafollicular-to-follicular transition of human B lymphocytes: induction of functional globotriaosylceramide (CD77) on high threshold occupancy of CD40. Eur J Immunol (1999) 0.96
5-Hydroxytryptamine drives apoptosis in biopsylike Burkitt lymphoma cells: reversal by selective serotonin reuptake inhibitors. Blood (2002) 0.96
Preferential cell death of CD8+ effector memory (CCR7-CD45RA-) T cells by hydrogen peroxide-induced oxidative stress. J Immunol (2005) 0.94
Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes. Clin Cancer Res (2004) 0.93
Potentiation of cellular antioxidant capacity by Bcl-2: implications for its antiapoptotic function. Biochem Pharmacol (2003) 0.92
The cytotoxicity of dopamine may be an artefact of cell culture. J Neurochem (2002) 0.92
Dopa inhibits induced proliferative activity of murine and human lymphocytes. Anticancer Res (1992) 0.90
Catecholaminergic suppression of immunocompetent cells. Immunol Today (1998) 0.90
Nuclear factor-kappa B is involved in the catecholaminergic suppression of immunocompetent cells. Ann N Y Acad Sci (2000) 0.87
Establishment and characterization of acute B-cell lymphocytic leukemia cell line showing (8;14) and (14;18) chromosome translocation. Acta Haematol (1990) 0.85
Primary CNS lymphoma. Semin Oncol (1999) 0.85
Repression of apoptosis in human B-lymphoma cells by CD40-ligand and Bcl-2: relationship to the cell-cycle and role of the retinoblastoma protein. Oncogene (1996) 0.84
Oxidation of proteinaceous cysteine residues by dopamine-derived H2O2 in PC12 cells. Arch Biochem Biophys (2002) 0.84
Evolving role of rituximab in the treatment of patients with non-Hodgkin's lymphoma. Future Oncol (2005) 0.82
Brain drug delivery system bearing dopamine hydrochloride for effective management of parkinsonism. Drug Dev Ind Pharm (1998) 0.79
Patients with HIV with Burkitt's lymphoma have a worse outcome than those with diffuse large-cell lymphoma also in the highly active antiretroviral therapy era. J Clin Oncol (2005) 0.78
Burkitt lymphoma in Papua New Guinea--40 years on. Ann Trop Paediatr (2005) 0.78
Increased dopamine content in lymphocytes from high-dose L-Dopa-treated Parkinson's disease patients. Neuroimmunomodulation (2005) 0.78
Pharmacological studies with several analogs of mazindol: correlation between effects on dopamine uptake and various in vivo responses. Eur J Pharmacol (1981) 0.77
Evaluation of rat striatal L-dopa and DA concentration after intraperitoneal administration of L-dopa prodrugs in liposomal formulations. J Control Release (2004) 0.77
Advances in the delivery of treatments for Parkinson's disease. Expert Opin Drug Deliv (2005) 0.77
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol (2010) 4.79
A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat Genet (2008) 4.37
Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood (2008) 3.85
Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood (2009) 3.50
BCL2/BCL-X(L) inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation. Blood (2011) 2.68
Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. Nat Genet (2010) 2.45
Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood (2009) 2.22
Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood (2006) 2.10
The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood (2010) 2.09
Characteristics of hospitalizations for patients who use a structured clinical care program for children with medical complexity. J Pediatr (2011) 2.08
A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood (2008) 1.93
Lymphocytes transport serotonin and dopamine: agony or ecstasy? Trends Immunol (2003) 1.79
Five members of the CEBP transcription factor family are targeted by recurrent IGH translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Blood (2006) 1.74
HVCN1 modulates BCR signal strength via regulation of BCR-dependent generation of reactive oxygen species. Nat Immunol (2010) 1.70
MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma. Blood (2003) 1.69
Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. Blood (2005) 1.51
Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin Lymphoma (2004) 1.51
Conformational change and mitochondrial translocation of Bax accompany proteasome inhibitor-induced apoptosis of chronic lymphocytic leukemic cells. Oncogene (2003) 1.49
Functional studies of BCL11A: characterization of the conserved BCL11A-XL splice variant and its interaction with BCL6 in nuclear paraspeckles of germinal center B cells. Mol Cancer (2006) 1.48
A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms. PLoS One (2009) 1.48
A high-density SNP genomewide linkage scan for chronic lymphocytic leukemia-susceptibility loci. Am J Hum Genet (2005) 1.43
Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. Blood (2002) 1.40
Voltage-gated proton channels maintain pH in human neutrophils during phagocytosis. Proc Natl Acad Sci U S A (2009) 1.39
Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. Blood (2002) 1.38
Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. J Clin Oncol (2009) 1.34
A high-density SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukemia. Blood (2007) 1.32
Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene (2002) 1.31
TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res (2005) 1.29
Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes. Hum Mol Genet (2004) 1.27
Common variation at 6p21.31 (BAK1) influences the risk of chronic lymphocytic leukemia. Blood (2012) 1.26
The Northwest Forest Plan: origins, components, implementation experience, and suggestions for change. Conserv Biol (2006) 1.25
Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res (2006) 1.22
High incidence of t(11;18)(q21;q21) in Helicobacter pylori-negative gastric MALT lymphoma. Blood (2002) 1.22
Interleukin 4-induced gene 1 is activated in primary mediastinal large B-cell lymphoma. Blood (2002) 1.21
Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells. Haematologica (2010) 1.17
Investigation on the possibility of biowaivers for ibuprofen. J Pharm Sci (2011) 1.13
Diminished sensitivity of chronic lymphocytic leukemia cells to ABT-737 and ABT-263 due to albumin binding in blood. Clin Cancer Res (2010) 1.12
Reductive activation of ricin and ricin A-chain immunotoxins by protein disulfide isomerase and thioredoxin reductase. Biochem Pharmacol (2004) 1.11
Non-voltage-gated L-type Ca2+ channels in human T cells: pharmacology and molecular characterization of the major alpha pore-forming and auxiliary beta-subunits. J Biol Chem (2004) 1.11
Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes. Blood (2005) 1.11
t(6;14)(p22;q32): a new recurrent IGH@ translocation involving ID4 in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Blood (2007) 1.10
Redox-signaling transmitted in trans to neighboring cells by melanoma-derived TNF-containing exosomes. Free Radic Biol Med (2007) 1.09
Barriers to effective TRAIL-targeted therapy of malignancy. J Clin Oncol (2007) 1.09
Protein profiling of plasma membranes defines aberrant signaling pathways in mantle cell lymphoma. Mol Cell Proteomics (2009) 1.07
The serotonin transporter (SLC6A4) is present in B-cell clones of diverse malignant origin: probing a potential anti-tumor target for psychotropics. FASEB J (2005) 1.07
Identification of Thr29 as a critical phosphorylation site that activates the human proton channel Hvcn1 in leukocytes. J Biol Chem (2009) 1.07
Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia. Genes Chromosomes Cancer (2014) 1.06
Hepatitis C virus association with peripheral blood B lymphocytes potentiates viral infection of liver-derived hepatoma cells. Blood (2008) 1.05
Identification of short-acting κ-opioid receptor antagonists with anxiolytic-like activity. Eur J Pharmacol (2011) 1.04
Serotonin excites neurons in the human submucous plexus via 5-HT3 receptors. Gastroenterology (2005) 1.02
Fine-scale mapping of the 6p25.3 chronic lymphocytic leukaemia susceptibility locus. Hum Mol Genet (2010) 1.02
pH regulation and beyond: unanticipated functions for the voltage-gated proton channel, HVCN1. Trends Cell Biol (2010) 1.01
Close encounters of the monoamine kind: immune cells betray their nervous disposition. Immunology (2005) 1.01
Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells. Blood (2002) 1.00
High-throughput sequencing analysis of the chromosome 7q32 deletion reveals IRF5 as a potential tumour suppressor in splenic marginal-zone lymphoma. Br J Haematol (2012) 1.00
ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets. Br J Haematol (2013) 0.99
TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2. Br J Haematol (2007) 0.98
Constitutive activation of the CD40 pathway promotes cell transformation and neoplastic growth. Oncogene (2005) 0.98
Type I cytokine profiles of human naïve and memory B lymphocytes: a potential for memory cells to impact polarization. Immunology (2006) 0.97
Defining the prognosis of early stage chronic lymphocytic leukaemia patients. Br J Haematol (2011) 0.96
5-Hydroxytryptamine drives apoptosis in biopsylike Burkitt lymphoma cells: reversal by selective serotonin reuptake inhibitors. Blood (2002) 0.96
Gains of REL in primary mediastinal B-cell lymphoma coincide with nuclear accumulation of REL protein. Genes Chromosomes Cancer (2007) 0.94
Interphase FISH assays for the detection of translocations with breakpoints in immunoglobulin light chain loci. Int J Cancer (2002) 0.94
Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen. Clin Cancer Res (2009) 0.94
Elevated circulating levels of thioredoxin and stress in chronic heart failure. Eur J Heart Fail (2004) 0.94
Epstein-Barr virus infection in vitro can rescue germinal center B cells with inactivated immunoglobulin genes. Blood (2005) 0.93
CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL. Leuk Res (2010) 0.93
Ofatumumab monotherapy in relapsed/refractory mantle cell lymphoma--a phase II trial. Br J Haematol (2014) 0.93
Identification and importance of N-glycosylation of the human 5-hydroxytryptamine3A receptor subunit. Biochem Pharmacol (2004) 0.92
Population depletion activates autonomous CD154-dependent survival in biopsylike Burkitt lymphoma cells. Blood (2002) 0.92
CD4-8- dendritic cells prime CD4+ T regulatory 1 cells to suppress antitumor immunity. J Immunol (2005) 0.92
Trisomy 19 is associated with trisomy 12 and mutated IGHV genes in B-chronic lymphocytic leukaemia. Br J Haematol (2007) 0.92
Positive MRI contrast enhancement in THP-1 cells with Gd2O3 nanoparticles. Contrast Media Mol Imaging (2008) 0.92
Multiphoton microscopy of transdermal quantum dot delivery using two photon polymerization-fabricated polymer microneedles. Faraday Discuss (2011) 0.92
Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein. Int J Cancer (2006) 0.91
Insight into the pathogenesis of chronic lymphocytic leukemia (CLL) through analysis of IgVH gene usage and mutation status in familial CLL. Blood (2008) 0.91
Cardiovascular mortality and N-terminal-proBNP reduced after combined selenium and coenzyme Q10 supplementation: a 5-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens. Int J Cardiol (2012) 0.91
ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele. Haematologica (2011) 0.91
Chromosomal translocations fusing the BCL6 gene to different partner loci are recurrent in primary central nervous system lymphoma and may be associated with aberrant somatic hypermutation or defective class switch recombination. J Neuropathol Exp Neurol (2006) 0.90
Molecular characterization of neoplastic and normal "sister" lymphoblastoid B-cell lines from chronic lymphocytic leukemia. Leuk Lymphoma (2013) 0.90
The CBFA2T3/ACSF3 locus is recurrently involved in IGH chromosomal translocation t(14;16)(q32;q24) in pediatric B-cell lymphoma with germinal center phenotype. Genes Chromosomes Cancer (2012) 0.90
BCL2 expression in chronic lymphocytic leukemia: lack of association with the BCL2 938A>C promoter single nucleotide polymorphism. Blood (2007) 0.90
GeneChip analyses point to novel pathogenetic mechanisms in mantle cell lymphoma. Br J Haematol (2008) 0.90
Enhanced Fas-associated death domain recruitment by histone deacetylase inhibitors is critical for the sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis. Mol Cancer Ther (2009) 0.90
Drug cross-resistance and therapy-induced resistance in chronic lymphocytic leukaemia by an enhanced method of individualised tumour response testing. Br J Haematol (2009) 0.89
Genetic variation in CXCR4 and risk of chronic lymphocytic leukemia. Blood (2009) 0.89
B-lymphocyte subpopulations are equally susceptible to Epstein-Barr virus infection, irrespective of immunoglobulin isotype expression. Immunology (2003) 0.89
SLC6A4 expression and anti-proliferative responses to serotonin transporter ligands chlomipramine and fluoxetine in primary B-cell malignancies. Leuk Res (2010) 0.88